Immunotactoid glomerulopathy associated with monoclonal gammopathy

The Lancet ◽  
2021 ◽  
Vol 397 (10289) ◽  
pp. 2081
Author(s):  
Satoshi Inotani ◽  
Taro Horino ◽  
Masayuki Ishihara ◽  
Osamu Ichii ◽  
Akinori Matsumori
Keyword(s):  
Monoclonal Gammopathy ◽  
Immunotactoid Glomerulopathy

scholarly journals A case of immunotactoid glomerulopathy in a patient with monoclonal gammopathy of renal significance

2021 ◽  
Vol 11 (1) ◽  
pp. 60-64
Author(s):  
Victoria Campdesuner ◽  
Yeshanew Teklie ◽  
Natalia Lattanzio ◽  
Christian Lorenzo ◽  
Stephen Bell ◽  
...  
Keyword(s):  
Monoclonal Gammopathy ◽  
Immunotactoid Glomerulopathy

scholarly journals Monoclonal Gammopathy of Renal Significance: Clinical and Histological Efficacy of a Bortezomib-Based Regimen

2020 ◽  
Vol 7 ◽  
Author(s):  
Giacomo Quattrocchio ◽  
Antonella Barreca ◽  
Antonella Vaccarino ◽  
Giulio Del Vecchio ◽  
Emanuele De Simone ◽  
...  
Keyword(s):  
Membranoproliferative Glomerulonephritis ◽  
Monoclonal Gammopathy ◽  
Filtration Rate ◽  
Estimated Glomerular Filtration Rate ◽  
Cell Clone ◽  
Dramatic Improvement ◽  
Complete Disappearance ◽  
Monoclonal Immunoglobulin ◽  
Immunotactoid Glomerulopathy ◽  
Chemotherapy Protocol

Monoclonal Gammopathy of Renal Significance (MGRS) is a group of heterogeneous disorders characterized by renal dysfunction secondary to the production of a monoclonal immunoglobulin by a nonmalignant B cell or plasma cell clone. We report the clinical and histological outcomes of two patients with biopsy-proven MGRS: one patient showed membranoproliferative glomerulonephritis with monoclonal k-light chain and C3 deposits, the second patient showed immunotactoid glomerulopathy. Both patients were treated with a 9-month chemotherapy protocol including bortezomib, cyclophosphamide, and dexamethasone. Renal biospy was repeated after 1 year. The estimated glomerular filtration rate (eGFR) increased from 22.5 (baseline) to 40 ml/min per 1.73 m2 after 12 months, then to 51.5 ml/min per 1.73 m2 after 24 months; proteinuria decreased from 4.85 (baseline) to 0.17 g/day after 12 months, then to 0.14 g/day after 24 months. Repeat renal biopsies showed a dramatic improvement of the glomerular proliferative lesions and near complete disappearance of the immune deposits. A bortezomib-based treatment proved very effective and was well-tolerated in the two patients presenting with clinically and histologically aggressive MGRS.

Immunotactoid glomerulopathy with massive bone marrow deposits in a patient with IgM kappa monoclonal gammopathy and hypocomplementemia

2001 ◽  
Vol 38 (2) ◽  
pp. 395-399 ◽  
Author(s):  
Nael Da[apos ]as ◽  
Yosef Kleinman ◽  
Aaron Polliack ◽  
Gail Amir ◽  
Zvi Ne[apos ]eman ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Monoclonal Gammopathy ◽  
Immunotactoid Glomerulopathy ◽  
Massive Bone

scholarly journals A Rare case of Monoclonal Gammopathy of Renal Significance with Immunotactoid Glomerulopathy Responding to Bortezomib, Dexamethasone and Rituximab

2020 ◽  
Author(s):  
Chaoyuan Kuang ◽  
Kevin Quann ◽  
Agnes Liman ◽  
Roy Frye ◽  
Nawras Alshoubaki ◽  
...  
Keyword(s):  
Monoclonal Gammopathy ◽  
Rare Case ◽  
Immunotactoid Glomerulopathy

Monoclonal gammopathy in scleredema. Observations in three cases

1981 ◽  
Vol 117 (9) ◽  
pp. 536-539 ◽  
Author(s):  
P. M. Kovary
Keyword(s):  
Monoclonal Gammopathy

Monoclonal gammopathy in lymphoma

1975 ◽  
Vol 135 (1) ◽  
pp. 62-66 ◽  
Author(s):  
R. Alexanian
Keyword(s):  
Monoclonal Gammopathy
Sign in / Sign up

Export Citation Format

Share Document